Whats new

Whats new.

Maxim Group - New Efti Trial Announced in Sarcoma; Moving into Neoadjuvant Setting; Buy, $8 tgt (Jason McCarthy, PhD)

April 19th 2023

For a copy of this analyst report please contact your Maxim advisor

Go back